New drug shows promise for slowing kidney disease in Non-Diabetic patients

NCT ID NCT06835322

Completed Disease control Sponsor: Alexandria University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether finerenone, a drug that blocks a hormone involved in kidney damage, can reduce protein in urine and slow kidney function decline. One hundred adults with non-diabetic glomerulonephritis took either finerenone or a placebo for 9 months, on top of their usual treatments. The goal is to see if finerenone can help protect the kidneys from further damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Finerenone (a drug that blocks a hormone to protect the kidneys)
What this could lead to: If it works, finerenone could become an add-on treatment to slow kidney damage and delay dialysis or transplant in people with non-diabetic glomerulonephritis.
What could go wrong: This is a small, phase 2 trial with only 100 participants, so results may not apply to everyone. Finerenone can raise potassium levels, which is a known risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLOMERULONEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glomerulonephritis proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLOMERULONEPHRITIS

Contacts and locations

Locations

Faculty of Medicine, Aexandria University

Alexandria, 21526, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.